Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03642054 · ClinicalTrials.gov registry record

Advanced Biomarker Assessment in Pelvic Organ Prolapse

A clinical trial of Pelvic Organ Prolapse, sponsored by Mayo Clinic.

Completed
Registry status
18
Enrollment target
1
Study location

NCT03642054: Completed study of Pelvic Organ Prolapse, sponsored by Mayo Clinic.

NCT03642054 is a study of Pelvic Organ Prolapse that has completed, run by Mayo Clinic. The registered enrollment target is 18 participants, below the 145-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03642054, a study of Pelvic Organ Prolapse, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
18 participants
Enrollment target
1
Study location

Study Summary

This study will assess advanced biomarkers in patients with and without vaginal prolapse. Assessments will be directed at vaginal fibroblasts and adipose derived stem cells.

Primary Outcome

RNA-Seq will determine if there are differences in mRNA or exon expression between cells from prolapse and normal patients, with focus on genes involved in connective tissue metabolism (e.g., collagens, MMPs, TIMPs, myofibroblast markers).

Conditions Studied

Study Locations (1)

Arizona

  • Mayo Clinic in Arizona - Phoenix

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-06-29
Est. Completion 2020-05-18
Mayo Clinic

2,844 total trials

What the finished NCT03642054 record still lists

NCT03642054 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 145-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Pelvic Organ Prolapse appearing as the primary indexed condition, and to 0 interventions.

NCT03642054 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT03642054 about?

NCT03642054 is a clinical study titled "Advanced Biomarker Assessment in Pelvic Organ Prolapse". This study will assess advanced biomarkers in patients with and without vaginal prolapse. Assessments will be directed at vaginal fibroblasts and adipose derived stem cells.

What is the current status of trial NCT03642054?

This trial is currently completed. The enrollment target is 18 participants. The study started on 2018-06-29. Estimated completion is 2020-05-18.

What conditions does trial NCT03642054 study?

This clinical trial studies the following conditions: Pelvic Organ Prolapse.

Who is sponsoring clinical trial NCT03642054?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03642054 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pelvic Organ Prolapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03642054's enrollment target sits among peer trials

18 41st of 40 the lowest of 40 other Pelvic Organ Prolapse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pelvic Organ Prolapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03642054, the US trial registry maintained by the National Library of Medicine. NCT03642054 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.